Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Degenerative Disc Disease - Overview
Degenerative Disc Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Degenerative Disc Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Degenerative Disc Disease - Companies Involved in Therapeutics Development
AnGes Inc
Bone Therapeutics SA
CHA Bio & Diostech Co Ltd
DiscGenics Inc
Kolon TissueGene Inc
U.S. Stem Cell Inc
Yuhan Corp
Degenerative Disc Disease - Drug Profiles
AdipoCell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLOB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-0103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBAC-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CybroCell - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTG-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy 1 for Degenerative Disc Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Degenerative Disc Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-0002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-14618 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Degenerative Disc Disease - Dormant Projects
Degenerative Disc Disease - Product Development Milestones
Featured News & Press Releases
Nov 14, 2018: Therapeutic potential of NTG-101, a single dose injectable treatment for Degenerative Disc Disease, demonstrated in preclinical large animal study published in ture Publishing Group’s "Scientific Reports"
Mar 20, 2018: USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas
Feb 28, 2018: USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference
Jan 15, 2018: USRM Reaches Key Sales Milestone of Proprietary Adipocell Product
Nov 28, 2017: Degenerative Disc Patients Significantly Improve With USRM’s Adipocell
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spil fusion trial
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB? Phase IIA spil fusion study
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spil Fusion at the ?Clinical Applications of Stem Cells’ Conference
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spil fusion trial
Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB? phase II trial in spine fusion
Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Degenerative Disc Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Degenerative Disc Disease, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Degenerative Disc Disease - Pipeline by AnGes Inc, H2 2019
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H2 2019
Degenerative Disc Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2019
Degenerative Disc Disease - Pipeline by DiscGenics Inc, H2 2019
Degenerative Disc Disease - Pipeline by Kolon TissueGene Inc, H2 2019
Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H2 2019
Degenerative Disc Disease - Pipeline by Yuhan Corp, H2 2019
Degenerative Disc Disease - Dormant Projects, H2 2019